Ira Goldknopf, president and chief scientific officer of Power3, said: “Power3 Medical is preparing to commercialize its BC SeraPro, and NuroPro tests for breast cancer, Alzheimer’s and Parkinson’s. The premarketing and packaging of the company’s early diagnostic test sample kits are complete, and ready for commercialization.
“Our partners in the foreign markets are primed as the points of release of the tests to the market. Our lab is positioned to run the tests in house with Clinical Laboratory Improvement Amendments certification. The initial launch is anticipated for Greece with completion of the clinical validation trials with The University of Thessaly.”